These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 7151077)
21. Acute electrophysiologic effects of pirmenol in normal subjects and in patients with Wolff-Parkinson-White syndrome. Brown JE; Yee R; Klein GJ Am J Cardiol; 1986 Apr; 57(10):775-81. PubMed ID: 3962864 [TBL] [Abstract][Full Text] [Related]
22. Beta-blocker therapy for the Wolff-Parkinson-White syndrome. Prystowsky EN; Greer S; Packer DL; Thompson KA; German LD Am J Cardiol; 1987 Aug; 60(6):46D-50D. PubMed ID: 2888300 [TBL] [Abstract][Full Text] [Related]
23. Effects of verapamil on accessory pathway properties and induction of circus movement tachycardia in patients with the Wolf-Parkinson-White syndrome. Matsuyama E; Konishi T; Okazaki H; Matsuda H; Kawai C J Cardiovasc Pharmacol; 1981; 3(1):11-24. PubMed ID: 6160340 [TBL] [Abstract][Full Text] [Related]
24. Effects of intravenous diltiazem administration in patients with inducible tachycardia. Waleffe A; Hastir F; Kulbertus HE Eur Heart J; 1985 Oct; 6(10):882-90. PubMed ID: 4076199 [TBL] [Abstract][Full Text] [Related]
25. Use of intracardiac recordings to determine the site of drug action in paroxysmal supraventricular tachycardia. Jackman WM; Friday KJ; Fitzgerald DM; Yeung-Lai-Wah JA; Lazzara R Am J Cardiol; 1988 Dec; 62(19):8L-19L. PubMed ID: 3059792 [TBL] [Abstract][Full Text] [Related]
26. Mechanism of reciprocating tachycardia initiated during sinus rhythm in concealed Wolff-Parkinson-White syndrome: report of a case. Sung RJ; Castellanos A; Gelband H; Myerburg RJ Circulation; 1976 Aug; 54(2):338-44. PubMed ID: 939032 [TBL] [Abstract][Full Text] [Related]
27. Effect of intravenous amiodarone on electrophysiologic variables and on the modes of termination of atrioventricular reciprocating tachycardia in Wolff-Parkinson-White syndrome. Kuga K; Yamaguchi I; Sugishita Y Jpn Circ J; 1999 Mar; 63(3):189-95. PubMed ID: 10201620 [TBL] [Abstract][Full Text] [Related]
28. Ethmozin. I. Effects of intravenous drug administration on paroxysmal supraventricular tachycardia in the ventricular preexcitation syndrome. Chazov EI; Shugushev KK; Rosenshtraukh LV Am Heart J; 1984 Sep; 108(3 Pt 1):475-82. PubMed ID: 6382988 [TBL] [Abstract][Full Text] [Related]
29. Efficacy of propafenone in Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up. Ludmer PL; McGowan NE; Antman EM; Friedman PL J Am Coll Cardiol; 1987 Jun; 9(6):1357-63. PubMed ID: 3294970 [TBL] [Abstract][Full Text] [Related]
30. [Effects of oral and injectable flecainide in patients with an accessory atrioventricular pathway]. Fauchier JP; Cosnay P; Rouesnel P; Moquet B; Bonnet P; Scala PJ; Demeyer JF Arch Mal Coeur Vaiss; 1985 Oct; 78 Spec No():81-90. PubMed ID: 3938264 [TBL] [Abstract][Full Text] [Related]
31. Electrophysiologic effects of intravenous propafenone in Wolff-Parkinson-White syndrome. Dubuc M; Kus T; Campa MA; Lambert C; Rosengarten M; Shenasa M Am Heart J; 1989 Feb; 117(2):370-6. PubMed ID: 2644795 [TBL] [Abstract][Full Text] [Related]
32. [Electrophysiologic properties of cibenzoline in Wolff-Parkinson-White syndrome and atrioventricular nodal reentry tachycardia]. Kühlkamp V; Ickrath O; Schmid F; Mayer F; Haasis R; Seipel L Z Kardiol; 1989 Oct; 78(10):640-6. PubMed ID: 2686251 [TBL] [Abstract][Full Text] [Related]
33. Electrophysiologic effects of lorcainide on the accessory pathway in the Wolff-Parkinson-White syndrome. Kasper W; Treese N; Meinertz T; Jähnchen E; Pop T Am J Cardiol; 1983 Jun; 51(10):1618-22. PubMed ID: 6858867 [TBL] [Abstract][Full Text] [Related]
34. [Cibenzoline: electrophysiologic effects of a new class I anti-arrhythmia agents in supraventricular tachycardia]. Pfitzner P; Manz M; Schütz R; Lüderitz B Z Kardiol; 1989 Oct; 78(10):654-60. PubMed ID: 2686252 [TBL] [Abstract][Full Text] [Related]
35. A possible mechanism of reciprocating tachycardia initiated by critical shortening of the atrial cycle length in concealed Wolff-Parkinson-White syndrome. Report of a case. Ohe T; Ejiri N; Kamakura S; Matsuhisa M; Hirata Y; Shimomura K Jpn Heart J; 1981 Jan; 22(1):135-42. PubMed ID: 7218523 [TBL] [Abstract][Full Text] [Related]
36. Effects of disopyramide on electrophysiological properties of specialized conduction system in man and on accessory atrioventricular pathway in Wolff-Parkinson-White syndrome. Spurrell RA; Thorburn CW; Camm J; Sowton E; Deuchar DC Br Heart J; 1975 Aug; 37(8):861-7. PubMed ID: 53057 [TBL] [Abstract][Full Text] [Related]
37. Clinical efficacy and electrophysiologic effects of intravenous and oral encainide in patients with accessory atrioventricular pathways and supraventricular arrhythmias. Abdollah H; Brugada P; Green M; Wehr M; Wellens HJ Am J Cardiol; 1984 Sep; 54(6):544-9. PubMed ID: 6433688 [TBL] [Abstract][Full Text] [Related]
38. Clinical efficacy and electrophysiologic effects of encainide in patients with Wolff-Parkinson-White syndrome. Prystowsky EN; Klein GJ; Rinkenberger RL; Heger JJ; Naccarelli GV; Zipes DP Circulation; 1984 Feb; 69(2):278-87. PubMed ID: 6418407 [TBL] [Abstract][Full Text] [Related]
39. Malignant ventricular arrhythmia in the Wolff-Parkinson-White syndrome during amiodarone treatment. Perticone F; Cuda G; Spadea F; Pintaudi C; Tropea R Clin Cardiol; 1987 Aug; 10(8):477-80. PubMed ID: 3621696 [TBL] [Abstract][Full Text] [Related]
40. [Electrophysiologic effects of penticainide in patients with supraventricular tachycardia]. Kühlkamp V; Mewis C; Mayer F; Seipel L Z Kardiol; 1990 Oct; 79(10):725-31. PubMed ID: 2087860 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]